Syndax Pharmaceuticals (SNDX) Assets Average (2016 - 2026)

Syndax Pharmaceuticals' Assets Average history runs 11 years deep, the most recent figure standing at $501.2 million for Q1 2026.

• In Q1 2026, Assets Average fell 26.59% year-over-year to $501.2 million; the TTM figure through Mar 2026 stood at $501.2 million (down 26.59% YoY), while the FY2025 annual figure was $627.3 million, down 6.22% from the prior year.
• Assets Average was $501.2 million for Q1 2026 at Syndax Pharmaceuticals, down from $540.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $682.8 million in Q1 2025 to a low of $383.1 million in Q3 2022.
• Historically, Assets Average has averaged $502.3 million across 5 years, with a median of $501.2 million in 2026.
• The sharpest annual moves came in 2022 and 2026: Assets Average surged 52.68% in 2022, then declined 26.59% in 2026.
• A 5-year view of Assets Average shows it stood at $428.5 million in 2022, then climbed by 18.11% to $506.1 million in 2023, then rose by 13.69% to $575.3 million in 2024, then decreased by 6.01% to $540.7 million in 2025, then decreased by 7.32% to $501.2 million in 2026.
• The last three Assets Average figures came in at $501.2 million (Q1 2026), $540.7 million (Q4 2025), and $574.0 million (Q3 2025), per Business Quant data.